Dendritic Cells Primed with Protein–Protein Fusion Adjuvant

To develop efficient T cell priming cancer vacciness, various recombinant fusion proteins have been developed by fusing a tumor antigen with a protein capable of stimulating or targeting dendritic cells (DC), the most important antigen-presenting cells for inducing CD8+ cytotoxic T lymphocytes (CTL) which can efficiently kill tumor cells expressing the tumor antigen. The DC-stimulating or DC-targeting proteins, including granulocyte/macrophage colony-stimulating factor (GM-CSF), anti-DEC-205 monoclonal antibodies, flagellin, and heat shock proteins (HSP), function as promising intermolecular adjuvants. Herein, we describe in vitro assays on human DC pulsed with HSP fusion proteins, which might be useful in preclinical studies for the screening and assessment of candidate cancer vacciness.
Source: Springer protocols feed by Cancer Research - Category: Cancer & Oncology Source Type: news